Measuring the improvement in health-related quality of life using King’s health questionnaire in non-obese and obese patients with lower urinary tract symptoms after alpha-adrenergic medication: a preliminary study

BMC Urology

Research Article

Soon-Sun Kwon¹  Byung Wook Yoo²  Ik Sung Lim³  Eun Seop Song⁴  Hoon Choi⁵  Hwa Yeon Sun⁶  Yun Seob Song⁶  Won Jae Yang⁶  Seung Whan Doo⁶  Jae Heon Kim⁶  Jong Hyun Yoon⁶  Joyce Mary Kim⁷  Hong Jun Lee⁸ 

[1] Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, South Korea;Department of Family Medicine, Soonchunhyang University School of Medicine, Seoul, South Korea;Department of Industrial Management and Engineering, Namseoul University College of Engineering, Cheonan, South Korea;Department of Obstetrics and Gynecology, Inha University School of Medicine, Incheon, South Korea;Department of Urology, Korea University College of Medicine, Ansan Hospital, Ansan, South Korea;Department of Urology, Soonchunhyang University College of Medicine, Seoul Hospital, 59, Daesagwan-ro, Yongsan-gu, 140-743, Seoul, Republic of Korea;International Clinic Center, Soonchunhyang University Hospital, Seoul, South Korea;Medical Research Institute, Chung-Ang University College of Medicine, Seoul, South Korea;

关键词: Alpha-blocker;    Prostatic hyperplasia;    Body mass index;    Waist circumference;   

DOI  :  10.1186/1471-2490-14-60

 received in 2014-04-24, accepted in 2014-07-31,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundThe efficacy of medical treatment among obese men with lower urinary tract symptoms (LUTS) has been less clear, especially regarding the improvement of QoL. We aimed to investigate the difference in efficacy and consequent satisfaction of life quality after medical treatment of male LUTS according to obesity.MethodsAn 8-week prospective study was performed for a total of 140 patients >50 years old with International Prostate Symptom Scores (IPSS) > 12 points and prostate volume > 20 mL. Obesity was determined by either body mass index (BMI) or waist circumference (WC). Patients were divided into 2 groups according to BMI or WC. Patients received tamsulosin at a dose of 0.4 mg daily for 8 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Qmax), post-void residual volume, questionnaire of quality of life (QoL), and King’s Health Questionnaire (KHQ) were analyzed.ResultsOf the 150 enrolled patients, 96 completed the study. Seventy-five patients (78.1%) had BMI ≥ 23 kg/m2, and 24 (25.0%) had WC > 90 cm. Overall, the IPSS, IPSS QoL, and total KHQ showed significant improvement. Obese (BMI ≥ 23 kg/m2) and non-obese (BMI < 23 kg/m2) both showed improvement of the IPSS and IPSS QoL scores, but only the obese (BMI ≥ 23 kg/m2) group showed improvement of the total KHQ score (P < 0.001 vs. P = 0.55). Only the obese (WC > 90 cm) group showed improvement of the IPSS and total KHQ scores (P < 0.001).ConclusionsOur preliminary study showed the different efficacy of an alpha-blocker for improvement of LUTS and life quality according to obesity. Obese patients, defined by BMI or WC, showed the tendency toward a more favorable improvement of LUTS and life quality.Trial registrationCurrent Controlled Trials 2010–058. Registered 2 September 2010 in Soonchunhyang Univeristy Hospital

【 授权许可】

Unknown   
© Kim et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.